GRAIL, Inc. is a biotechnology company focused on the early detection of cancer through innovative blood tests
The company is dedicated to advancing its proprietary multi-cancer early detection technology, which aims to identify various types of cancer in their earliest, most treatable stages. By utilizing advanced genomic science and machine learning techniques, GRAIL seeks to improve patient outcomes and transform the landscape of cancer diagnostics, ultimately contributing to earlier interventions and better survival rates.
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Grail shares are trading higher Wednesday after the company announced a new collaboration with Quest Diagnostics aimed at improving provider access to its Galleri multi-cancer early detection test.
GRAIL is a small biotech stock on the rise big time recently. Its innovative technology gives it the opportunity to capitalize on a massive addressable market.
Illumina welcomes the European Court of Justice ruling that the European Commission lacked jurisdiction over its acquisition of GRAIL, confirming Illumina's stance. The ruling nullifies a €432 million fine.
Wall Street continues to experience a series of memorable days, with the bulls riding the rally with increasing confidence, certain that the Federal Reserve will begin cutting interest rates in September.
